PUBLIC COMPANY
save$COMPCompass, Inc.
$COMP11.92-6.88%New York, NY, USupdated 3h ago
A compass is a device that shows the cardinal directions used for navigation and geographic orientation. It typically consists of a magnetized needle or another element, such as a compass card or compass rose, that pivots to align itself with magnetic north. Other methods may be used, including gyroscopes, magnetometers, and GPS receivers.
community read0 votes
pipeline
4
marketed
0
phase 3
1
catalysts ytd
5
approvals ytd
0
recalls ytd
0
Pipeline(4)
pipeline depth4 products
2Phase 11Phase 31Unknown
Upcoming
Recent(90d)
earnings (2)
Active trials
- phase1A Phase 1 Study of the Safety and Tolerability of CTX-10726
- phase3A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)
- phase2A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer
- phase1A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
- phase1Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Insider activity
source: SEC Form 4routine RSU / option mechanics (6)
- Mar 23, 26tax coverWahlers Scott R. · CFO18,103 sh
- Mar 23, 26grantWahlers Scott R. · CFO70,921 sh
- Mar 23, 26option exerciseWahlers Scott R. · CFO35,460 sh
- Mar 23, 26grantWahlers Scott R. · CFO196,199 sh
- Mar 23, 26grantGustavson Timothy B. · Chief Accounting Officer36,787 sh
- Mar 23, 26grantGustavson Timothy B. · Chief Accounting Officer15,750 sh
🐶 Hiring Signal
next earnings Nov 4, 2026
News
- Agios axes next-gen sickle cell candidate after it fails to best Novo’s assetAgios Pharmaceuticals’ sickle cell disease candidate didn’t prove any better than Novo Nordisk’s investigational PK activator or the biopharma’s own asset that is currently under FDA review for the…biospace · 1mo ago
- J&J sees Spravato sales surge as psychedelic competitors loomPsychedelics, chiefly Compass Pathways' COMP360, are unlikely to make an immediate dent in the sales of Johnson & Johnson’s depression drug Spravato, H.C. Wainwright’s Patrick Trucchio told BioSpace.biospace · 1mo ago
- 10 clinical trials to watch in the second half of 2026The biotechnology sector’s upswing accelerated in the first half. Positive results from anticipated trials in lung cancer, Alzheimer’s and multiple autoimmune conditions could add to the momentum.biopharma_dive · 1mo ago
- Opinion: ‘I’m pretty much all in’: An interview with a woman starting medical residency at almost 73"There are some physicians that work to 100”: Dawn Zuidgeest-Craft on becoming a medical doctor in her 70s.stat · 2mo ago
Data sources
last refreshed 35m ago
Found something off?
comments(0)
5-min edit window · permanent after that